Eli Lilly (LLY) stock news

Here are the 4 big things we're watching in the stock market in the week ahead

Both sides of the Fed's dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its obesity pipeline.

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.

Eli Lilly CEO offers investors 3 more reasons to stick with the stock

Encouraging updates from Eli Lilly CEO Dave Ricks strengthen the bull case for the stock.

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Twist Bioscience stock rises on Eli Lilly partnership deal

Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Notable Friday Option Activity: KHC, DVN, LLY

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Kraft Heinz Co (Symbol: KHC), where a total volume of 88,181 contracts has been traded thus far today, a contract volume…

Lilly looks beyond obesity with $2.88B autoimmune buyout

Lilly taps obesity windfall for more M&A. Plus, Elon Musk remarks pull GE Vernova lower

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more

These are some of the stocks posting the largest moves midday.

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?